Profile data is unavailable for this security.
About the company
Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
- Revenue in HKD (TTM)534.17m
- Net income in HKD-17.40m
- Incorporated2018
- Employees275.00
- LocationAbbisko Cayman LtdBuilding 3, No. 898Halei Road, Zhangjiang Hi-Tech ParkPudong New AreaSHANGHAI 200120ChinaCHN
- Phone+86 2 168912098
- Websitehttps://www.abbisko.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hua Medicine | 117.02m | -282.92m | 1.65bn | 172.00 | -- | -- | -- | 14.07 | -0.2886 | -0.2886 | 0.1194 | -0.0363 | 0.0779 | 1.51 | 3.31 | 661,157.10 | -18.84 | -25.61 | -23.63 | -28.81 | 37.72 | -- | -241.76 | -1,654.70 | 4.64 | -- | 1.14 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
| Qyuns Therapeutics Co Ltd | 48.25m | -453.10m | 1.98bn | 325.00 | -- | 5.02 | -- | 41.10 | -1.93 | -1.93 | 0.219 | 1.78 | -- | -- | -- | 145,775.50 | -- | -- | -- | -- | 84.05 | -- | -976.77 | -- | 1.83 | -29.56 | 0.5795 | -- | -- | -- | -70.28 | -- | -- | -- |
| Frontage Holdings Corp | 2.02bn | 47.47m | 2.18bn | 1.66k | 46.60 | 0.8315 | 6.44 | 1.08 | 0.023 | 0.023 | 0.988 | 1.29 | 0.4701 | 56.23 | 4.58 | 1,150,374.00 | 1.06 | 4.46 | 1.30 | 5.28 | 28.56 | 34.00 | 2.26 | 9.92 | 1.25 | 2.37 | 0.311 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
| Biocytogen Pharmaceuticals Beijng Co Ltd | 859.97m | -261.91m | 2.40bn | 1.04k | -- | 3.02 | -- | 2.79 | -0.6576 | -0.6576 | 2.16 | 1.99 | 0.3109 | 23.64 | 5.36 | 806,728.50 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -4.18 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
| CStone Pharmaceuticals | 490.40m | -152.87m | 2.56bn | 164.00 | -- | 5.09 | -- | 5.21 | -0.12 | -0.12 | 0.3847 | 0.3912 | 0.2861 | 1.33 | 2.50 | 2,132,195.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 404.97k | -402.17m | 2.74bn | 150.00 | -- | 4.25 | -- | 6,772.28 | -1.12 | -1.12 | 0.0011 | 1.72 | -- | -- | -- | 2,792.90 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| Abbisko Cayman Ltd | 534.17m | -17.40m | 3.15bn | 275.00 | -- | 1.41 | 886.04 | 5.89 | -0.0295 | -0.0295 | 0.8225 | 3.27 | 0.2159 | -- | 65.75 | 2,070,417.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 6.81m | -746.44m | 4.13bn | 477.00 | -- | 2.58 | -- | 605.92 | -1.34 | -1.34 | 0.0122 | 2.79 | 0.0027 | -- | 0.302 | 13,198.43 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Alphamab Oncology | 274.85m | -231.63m | 4.41bn | 429.00 | -- | 2.53 | -- | 16.04 | -0.2406 | -0.2406 | 0.2855 | 1.81 | 0.1145 | 0.8256 | 13.94 | 631,848.10 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
Data as of Nov 22 2024. Currency figures normalised to Abbisko Cayman Ltd's reporting currency: Hong Kong Dollar HKD
8.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 23 Nov 2023 | 23.31m | 3.43% |
| BlackRock Advisors LLCas of 30 Sep 2024 | 16.25m | 2.39% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 30 Sep 2024 | 6.60m | 0.97% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 5.84m | 0.86% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.67m | 0.39% |
| Invesco Hong Kong Ltd.as of 30 Sep 2024 | 2.02m | 0.30% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 Jul 2024 | 223.00k | 0.03% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 211.00k | 0.03% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 100.00k | 0.02% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 79.00k | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
